Lake Region Healthcare Corporation-Cancer Care

Summary

Lake Region Healthcare Corporation-Cancer Care is a medical facility located in Fergus Falls, Minnesota. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Lake Region Healthcare Corporation-Cancer Care is involved with conducting 131 clinical trials across 288 conditions. There are 2 research doctors associated with this hospital, such as Bret E. Friday and Bret EB Friday.

Top PIs

Clinical Trials running at Lake Region Healthcare Corporation-Cancer Care

Bladder Cancer

Bladder Carcinoma

Lung Cancer

Cutaneous Melanoma

Kidney Cancer

Melanoma

Laryngeal Cancer

Pancreatic Neuroendocrine Tumors

Non-Small Cell Lung Cancer

Oropharyngeal Carcinoma

Gemcitabine + Cisplatin

for Bladder Cancer

This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Recruiting

1 award

Phase 2

Immunotherapy + Targeted Therapy

for Genitourinary Cancers

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Recruiting

1 award

Phase 2

21 criteria